Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors

Journal of Medicinal Chemistry

Volumn 56, Issue 11, 2013, Pages 4277-4299

  Vitale, Paola ^a   Tacconelli, Stefania ^c,e   Perrone, Maria Grazia ^a   Malerba, Paola ^a   Simone, Laura ^a   Scilimati, Antonio ^a   Lavecchia, Antonio ^b   Dovizio, Melania ^c,e   Marcantoni, Emanuela ^c,e   Bruno, Annalisa ^d,e   Patrignani, Paola ^c,e  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Department of Neuroscience and Imaging ^*  (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e Center of Excellence on Aging (CeSI)   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 (5 CHLOROFURAN 2 YL) 4 PHENYL 5 (TRIFLUOROMETHYL) ISOXAZOLE; ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; ISOXAZOLE DERIVATIVE; THROMBOXANE; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; CYCLOADDITION; DRUG BINDING; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; IC 50; IN VITRO STUDY; LOW DRUG DOSE; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION;

ANIMALS; BLOOD PLATELETS; CELL LINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; EPOPROSTENOL; FEMALE; FIBRINOLYTIC AGENTS; FURANS; HUMANS; ISOXAZOLES; MICE; MICE, INBRED C57BL; MOLECULAR DOCKING SIMULATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET-RICH PLASMA; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOXANE A2;

EID: 84879062991     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301905a     Document Type: Article

References (79)

1. Smith, E. M.; Grosser, T.; Wang, M.; Yu, Y.; FitzGerald, G. A. Prostanoids in health and disease J. Lipid Res. 2009, 50, S423-428
2. Rocca, B.; Spain, L. M.; Puré, E.; Langenbach, R.; Patrono, C.; FitzGerald, G. A. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development J. Clin. Invest. 1999, 103, 1469-1477 (Pubitemid 29535503)
3. Simmons, D. L.; Botting, R. M.; Hla, T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition Pharmacol. Rev. 2004, 56, 387-437 (Pubitemid 39096597)
4. Patrono, C.; Patrignani, P.; García Rodríguez, L. A. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs J. Clin. Invest. 2001, 108, 7-13 (Pubitemid 32634915)
5. Belton, O. A.; Duffy, A.; Toomey, S.; Fitzgerald, D. J. Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis Circulation 2003, 108, 3017-2303
6. Praticò, D.; Tillmann, C.; Zhang, Z. B.; Li, H.; FitzGerald, G. A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3358-3363 (Pubitemid 32220850)
7. McClelland, S.; Gawaz, M.; Kennerknecht, E.; Konrad, C. S.; Sauer, S.; Schuerzinger, K.; Massberg, S.; Fitzgerald, D. J.; Belton, O. Contribution of cyclooxygenase-1 to thromboxane formation, platelet-vessel wall interactions and atherosclerosis in the ApoE null mouse Atherosclerosis 2009, 202, 84-91
8. Chulada, P. C.; Thompson, M. B.; Mahler, J. F.; Doyle, C. M.; Gaul, B. W.; Lee, C.; Tiano, H. F.; Morham, S. G.; Smithies, O.; Langenbach, R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice Cancer Res. 2000, 60, 4705-4708
9. Daikoku, T.; Wang, D.; Tranguch, S.; Morrow, J. D.; Orsulic, S.; DuBoi,s, R. N.; Dey, S. K. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer Cancer Res. 2005, 65, 3735-3744 (Pubitemid 40616351)
10. Perrone, M. G.; Scilimati, A.; Simone, L.; Vitale, P. Selective COX-1 inhibition: a therapeutic target to be reconsidered Curr. Med. Chem. 2010, 17, 3769-3805
11. Patrono, C.; García Rodríguez, L. A.; Landolfi, R.; Baigent, C. Low-dose aspirin for the prevention of atherothrombosis N. Engl. J. Med. 2005, 353, 2373-2383 (Pubitemid 41713749)
12. Patrono, C.; Baigent, C.; Hirsh, J.; Roth, G. American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition) Chest 2008, 133, 199S-233S (Pubitemid 351894914)
13. Patrignani, P.; Filabozzi, P.; Patrono, C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects J. Clin. Invest. 1982, 69, 1366-1372 (Pubitemid 12081064)
14. Reilly, I. A.; FitzGerald, G. A. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs Blood 1987, 69, 180-186 (Pubitemid 17007095)
15. Minuz, P.; Fumagalli, L.; Gaino, S.; Tommasoli, R. M.; Degan, M.; Cavallini, C.; Lecchi, A.; Cattaneo, M.; Lechi Santonastaso, C.; Berton, G. Rapid stimulation of tyrosine phosphorylation signals downstream of G protein-coupled receptors for thromboxane A2 in human platelets Biochem. J. 2006, 400, 127-134 (Pubitemid 44763827)
16. Vinik, A. I.; Erbas, T.; Park, T. S.; Nolan, R.; Pittenger, G. L. Platelet dysfunction in type 2 diabetes Diabetes Care 2001, 24, 1476-1485 (Pubitemid 33716440)
17. Evangelista, V.; Manarini, S.; Di Santo, A.; Capone, M. L.; Ricciotti, E.; Di Francesco, L.; Tacconelli, S.; Sacchetti, A.; D'Angelo, S.; Scilimati, A.; Sciulli, M. G.; Patrignani, P. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin Circ. Res. 2006, 98, 593-595
18. Grosser, T.; Smyth, E.; Fitzgerald, G. A. Anti-Inflammatory, Antipyretic, and Analgesic Agents: Pharmacotherapy of Gout. In Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12 th ed.; Brunton, L. L.; Blumenthal, D. K.; Murri, N.; Dandan, R. H.; Knollmann, B. C., Eds.; McGraw-Hill: New York, 2011; pp 962-992.
19. Capone, M. L.; Tacconelli, S.; Sciulli, M. G.; Grana, M.; Ricciotti, E.; Minuz, P.; Di Gregorio, P.; Merciaro, G.; Patrono, C.; Patrignani, P. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects Circulation 2004, 109, 1468-1471 (Pubitemid 38420172)
20. García Rodríguez, L. A.; Tacconelli, S.; Patrignani, P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population J. Am. Coll. Cardiol. 2008, 52, 1628-1636
21. Capone, M. L.; Sciulli, M. G.; Tacconelli, S.; Grana, M.; Ricciotti, E.; Renda, G.; Di Gregorio, P.; Merciaro, G.; Patrignani, P. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects J. Am. Coll. Cardiol. 2005, 45, 1295-1301 (Pubitemid 40523153)
22. Capone, M. L.; Tacconelli, S.; Sciulli, M. G.; Anzellotti, P.; Di Francesco, L.; Merciaro, G.; Di Gregorio, P.; Patrignani, P. Human pharmacology of naproxensodium J. Pharmacol. Exp. Ther. 2007, 322, 453-460
23. Grosser, T.; Fries, S.; FitzGerald, G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities J. Clin. Invest. 2006, 116, 4-15 (Pubitemid 43121782)
24. Massó González, E. L.; Patrignani, P.; Tacconelli, S.; García Rodríguez, L. A. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding Arthritis Rheum. 2010, 62, 1592-1601
25. Tanaka, A.; Araki, H.; Komoike, Y.; Hase, S.; Takeuchi, K. Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal anti-inflammatory drugs J. Physiol. 2001, 95, 21-27 (Pubitemid 33020214)
26. Patrono, C.; Patrignani, P.; García Rodríguez, L. A. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs J. Clin. Invest. 2001, 108, 7-13 (Pubitemid 32634915)
27. Dovizio, M.; Bruno, A.; Tacconelli, S.; Patrignani, P. Mode of action of aspirin as a chemopreventive agent Recent Results Cancer Res. 2013, 191, 39-65
28. Rothwell, P. M.; Wilson, M.; Elwin, C. E.; Norrving, B.; Algra, A.; Warlow, C. P.; Meade, T. W. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials Lancet 2010, 376, 1741-1750
29. Rothwell, P. M.; Fowkes, F. G.; Belch, J. F.; Ogawa, H.; Warlow, C. P.; Meade, T. W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials Lancet 2011, 377, 31-41
30. Chulada, P. C.; Thompson, M. B.; Mahler, J. F.; Doyle, C. M.; Gaul, B. W.; Lee, C.; Tiano, H. F.; Morham, S. G.; Smithies, O.; Langenbach, R. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice Cancer Res. 2000, 60, 4705-4758
31. Di Nunno, L.; Vitale, P.; Scilimati, A.; Tacconelli, S.; Patrignani, P. Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal COX-2 selectivity by sulfonamide group removal J. Med. Chem. 2004, 47, 4881-4890 (Pubitemid 39238263)
32. Perrone, M. G.; Vitale, P.; Malerba, P.; Altomare, A.; Rizzi, R.; Lavecchia, A.; Di Giovanni, C.; Novellino, E.; Scilimati, A. Diarylheterocycle core ring features effect in selective COX-1 inhibition ChemMedChem 2012, 7, 629-641
33. Patrignani, P.; Panara, M. R.; Greco, A.; Fusco, O.; Natoli, C.; Iacobelli, S.; Cipollone, F.; Ganci, A.; Creminon, C.; Maclouf, J.; Patrono, C. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases J. Pharmacol. Exp. Ther. 1994, 271, 1705-1721
34. Patrono, C.; Ciabattoni, G.; Pinca, E.; Pugliese, F.; Castrucci, G.; De Salvo, A.; Satta, M. A.; Peskar, B. A. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects Thromb. Res. 1980, 17, 317-327 (Pubitemid 10129020)
35. Swinney, D. C.; Mak, A. Y.; Barnett, J.; Ramesha, C. S. Differential allosteric regulation of prostaglandin H synthase 1 and 2 by arachidonic acid J. Biol. Chem. 1997, 272, 12393-12398 (Pubitemid 27203326)
36. FitzGerald, G. A.; Pedersen, A. K.; Patrono, C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease Circulation. 1983, 67, 1174-1177 (Pubitemid 13105335)
37. Tang, C.; Shou, M.; Mei, Q.; Rushmore, T. H.; Rodrigues, A. D. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor J. Pharmacol. Exp. Ther. 2000, 293, 453-459 (Pubitemid 30244094)
38. Zhang, J. Y.; Yuan, J. J.; Wang, Y. F.; Bible, R. H.; Breau, A. P. Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice Drug Metab. Dispos. 2003, 31, 491-501 (Pubitemid 36378528)
39. Tsai, A.; Kulmacz, R. Prostaglandin H synthase: resolved and unresolved mechanistic issues Arch. Biochem. Biophys. 2010, 493, 103-124
40. Walker, M.; Kurumbail, R.; Kiefer, J.; Moreland, K.; Koboldt, C.; Isakson, P.; Seibert, K.; Gierse, J. A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors Biochem. J. 2001, 357, 709-718 (Pubitemid 32735151)
41. Blobaum, A.; Marnett, L. Structural and functional basis of cyclooxygenase inhibition J. Med. Chem. 2007, 50, 1425-1441 (Pubitemid 46564365)
42. Ricciotti, E.; Dovizio, M.; Di Francesco, L.; Anzellotti, P.; Salvatore, T.; Di Francesco, A.; Sciulli, M. G.; Pistritto, G.; Monopoli, A.; Patrignani, P. NCX 4040, a nitric oxide-donating aspirin, exerts anti-inflammatory effects through inhibition of I kappa B-alpha degradation in human monocytes J. Immunol. 2010, 184, 2140-2147
43. Cyrus, T.; Sung, S.; Zhao, L.; Funk, C. D.; Tang, S.; Praticò, D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice Circulation 2002, 106, 1282-1287 (Pubitemid 34988649)
44. Brater, D. C.; Harris, C.; Redfern, J. S.; Gertz, B. J. Renal effects of COX-2-selective inhibitors Am. J. Nephrol. 2001, 21, 1-15 (Pubitemid 32238607)
45. Ciabattoni, G.; Boss, A. H.; Patrignani, P.; Catella, F.; Simonetti, B. M.; Pierucci, A.; Pugliese, F.; Filabozzi, P.; Patrono, C. Effects of sulindac on renal and extrarenal eicosanoid synthesis Clin. Pharmacol. Ther. 1987, 41, 380-383 (Pubitemid 17058920)
46. Nasrallah, R.; Hébert, R. L. Prostacyclin signaling in the kidney: implications for health and disease Am. J. Physiol.: Renal Physiol. 2005, 289, F235-F246
47. Rimon, G.; Sidhu, R. S.; Lauver, D. A.; Lee, J. Y.; Sharma, N. P.; Yuan, C.; Frieler, R. A.; Trievel, R. C.; Lucchesi, B. R.; Smith, W. L. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1 Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 28-33
48. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 1997, 267, 727-748 (Pubitemid 27170693)
49. Bottegoni, G.; Cavalli, A.; Recanatini, M. A comparative study on the application of hierarchical-agglomerative clustering approaches to organize outputs of reiterated docking runs J. Chem. Inf. Model. 2006, 46, 852-862
50. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by antiinflammatory agents Nature (London) 1996, 384, 644-648
51. Thuresson, E. D.; Malkowski, M. G.; Lakkides, K. M.; Rieke, C. J.; Mulichak, A. M.; Ginell, S. L.; Garavito, R. M.; Smith, W. L. Mutational and X-ray crystallographic analysis of the interaction of dihomo-gamma-linolenic acid with prostaglandin endoperoxide H synthases J. Biol. Chem. 2001, 276, 10358-10365
52. Gupta, K.; Selinsky, B. S.; Kaub, C. J.; Katz, A. K.; Loll, P. J. The 2.0 Å resolution crystal structure of prostaglandin H2 synthase-1: structural insights into an unusual peroxidase J. Mol. Biol. 2004, 335, 503-518 (Pubitemid 37532652)
53. Vecchio, A. J.; Simmons, D. M.; Malkowski, M. G. Structural basis of fatty acid substrate binding to cyclooxygenase-2 J. Biol. Chem. 2010, 285, 22152-22163
54. Luong, C.; Miler, A.; Barnett, J.; Chow, J.; Ramesha, C.; Browner, M. F. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 Nat. Struct. Biol. 1996, 3, 927-933 (Pubitemid 26398325)
55. Bhattacharyya, D. K.; Lecomte, M.; Rieke, C. J.; Garavito, M.; Smith, W. L. Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1 J. Biol. Chem. 1996, 271, 2179-2184
56. Yuan, C.; Rieke, C. J.; Rimon, G.; Wingerd, B. A.; Smith, W. L. Partnering between monomers of cyclooxygenase-2 homodimers Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 6142-6147
57. Yuan, C.; Sidhu, R. S.; Kuklev, D. V.; Kado, Y.; Wada, M.; Song, I.; Smith, W. L. Cyclooxygenase allosterism, fatty acid-mediated cross-talk between monomers of cyclooxygenase homodimers J. Biol. Chem. 2009, 284, 10046-10055
58. Sidhu, R.; Lee, J.; Yuan, C.; Smith, W. Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers Biochemistry 2010, 49, 7069-7079
59. Mbonye, U. R.; Yuan, C.; Harris, C. E.; Sidhu, R. S.; Song, I.; Arakawa, T.; Smith, W. L. Two distinct pathways for cyclooxygenase-2 protein degradation J. Biol. Chem. 2008, 283, 8611-8623
60. Prusakiewicz, J. J.; Duggan, K. C.; Rouzer, C. A.; Marnett, L. J. Differential sensitivity and mechanism of inhibition of COX-2 oxygenation of arachidonic acid and 2-arachidonoylglycerol by ibuprofen and mefenamic acid Biochemistry 2009, 48, 7353-7355
61. Zou, H.; Yuan, C.; Dong, L.; Sidhu, R. S.; Hong, Y. H.; Kuklev, D. V.; Smith, W. L. Human cyclooxygenase-1 activity and its responses to COX inhibitors are allosterically regulated by nonsubstrate fatty acids J. Lipid Res. 2012, 53, 1336-1347
62. Dong, L.; Vecchio, A. J.; Sharma, N. P.; Jurban, B. J.; Malkowski, M. G.; Smith, W. L. Human cyclooxygenase-2 is a sequence homodimer that functions as a conformational heterodimer J. Biol. Chem. 2011, 286, 19035-19046
63. Loll, P. J.; Picot, D.; Ekabo, O.; Garavito, R. M. The synthesis and use of iodinated non-steroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site Biochemistry 1996, 35, 7330-7340 (Pubitemid 26191283)
64. Lanzo, C. A.; Sutin, J.; Rowlinson, S.; Talley, J.; Marnett, L. J. Fluorescence quenching analysis of the association and dissociation of a diarylheterocycle to cyclooxygenase-1 and cyclooxygenase-2: dynamic basis of cyclooxygenase-2 selectivity Biochemistry 2000, 39, 6228-6234 (Pubitemid 30327100)
65. Suffert, J. Simple direct titration of organolithium reagents using N -pivaloyl- o -toluidine and/or N -pivaloyl- o -benzylaniline J. Org. Chem. 1989, 54, 509-510
66. Di Nunno, L.; Scilimati, A. Synthesis of 3-aryl-4, 5-dihydro-5-hydroxy-1, 2-oxazoles by reaction of substituted benzonitrile oxides with the enolate ion of acetaldehyde Tetrahedron 1987, 43, 2181-2189
67. Di Nunno, L.; Scilimati, A.; Vitale, P. Regioselective synthesis and side-chain metallation and elaboration of 3-aryl-5-alkylisoxazoles Tetrahedron 2002, 58, 2659-2665 (Pubitemid 34251154)
68. 2,5]octan- 4,8-diones induced by hindered lithium amides Tetrahedron 2007, 63, 12388-12395 (Pubitemid 350016164)
69. Di Nunno, L.; Scilimati, A.; Vitale, P. Reaction of 3-phenylisoxazole with alkyllithiums Tetrahedron 2005, 61, 2623-2630 (Pubitemid 40255227)
70. 2,5]octan-4,8-diones induced by LDA Tetrahedron 2008, 64, 11198-11204
71. Di Nunno, L.; Scilimati, A.; Vitale, P. 5-Hydroxy-3-phenyl-5-vinyl-2- isoxazoline and 3-phenyl-5-vinylisoxazole: synthesis and reactivity Tetrahedron 2005, 61, 11270-11278 (Pubitemid 41502905)
72. Scilimati, A.; Vitale, P.; Di Nunno, L.; Patrignani, P.; Tacconelli, S.; Capone, M. L. Functionalized Diarylisoxazoles Inhibitors of Cyclooxygenase. U.S. Patent 7,989,450 B2, 2011.
73. Pedersen, A. K.; FitzGerald, G. A. Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing Clin. Pharmacol. Ther. 1985, 37, 36-42 (Pubitemid 16225164)
74. Ouellet, M.; Riendeau, D.; Percival, M. D. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 14583-14588 (Pubitemid 33121435)
75. Di Francesco, L.; Totani, L.; Dovizio, M.; Piccoli, A.; Di Francesco, A.; Salvatore, T.; Pandolfi, A.; Evangelista, V.; Dercho, R. A.; Seta, F.; Patrignani, P. Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human endothelial cells Circ. Res. 2009, 104, 506-513
76. Ciabattoni, G.; Pugliese, F.; Davi, G.; Pierucci, A.; Simonetti, B. M.; Patrono, C. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man Biochim. Biophys. Acta 1989, 992, 66-70 (Pubitemid 19179025)
77. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-a visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612
78. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific: San Carlos, CA, 2002.
79. Lovell, S. C.; Word, J. M.; Richardson, J. S.; Richardson, D. C. The penultimate rotamer library Proteins 2000, 40, 389-408 Nazionale